-transparent.png){kind=logo}
We compared a commercial radioimmunoassay kit with an enzymatic assay for prostatic acid phosphatase in monitoring the progression or remission of disease in 27 patients with prostatic cancer. In 5 of the 18 patients whose disease progressed, and in 4 of the 9 whose disease responded to treatment, the change was reflected better by the radioimmunoassay. In no case was the enzymatic assay better. Radioimmunoassay for prostatic acid phosphatase may be an effective and sensitive way to monitor the course of carcinoma of the prostate.
Related Publications
T D Moon, and
R L Vessella, and
M Eickhoff, and
P H Lange
April 1984,
British journal of urology,
T D Moon, and
R L Vessella, and
M Eickhoff, and
P H Lange
January 1980,
The Prostate,
T D Moon, and
R L Vessella, and
M Eickhoff, and
P H Lange
January 1977,
Clinical chemistry,
T D Moon, and
R L Vessella, and
M Eickhoff, and
P H Lange
November 1980,
The Journal of urology,
T D Moon, and
R L Vessella, and
M Eickhoff, and
P H Lange
January 1984,
Urological research,
T D Moon, and
R L Vessella, and
M Eickhoff, and
P H Lange
January 1981,
Acta urologica Belgica,
T D Moon, and
R L Vessella, and
M Eickhoff, and
P H Lange
October 1980,
The Urologic clinics of North America,
T D Moon, and
R L Vessella, and
M Eickhoff, and
P H Lange
November 1980,
JAMA,
T D Moon, and
R L Vessella, and
M Eickhoff, and
P H Lange
November 1986,
Clinica chimica acta; international journal of clinical chemistry,
T D Moon, and
R L Vessella, and
M Eickhoff, and
P H Lange
December 1978,
National Cancer Institute monograph,
